Synthesis, structure-activity relationships of carnosol derivatives for cancer-associated cachexia

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Cancer cachexia is characterized by muscle atrophy and metabolic dysfunction, presenting a major clinical challenge.
• Carnosol, a natural compound, suffers from metabolic instability, limiting its therapeutic potential.

Purpose of the Study:

• To design and identify metabolically stable carnosol derivatives for treating cancer cachexia.
• To evaluate the efficacy of optimized carnosol derivatives in preclinical models of cancer cachexia.

Main Methods:

• Synthesized 35 carnosol derivatives, modifying oxidation-prone phenolic groups with oxazole or aryl moieties.
• Conducted structure-activity relationship (SAR) studies to identify lead compounds.
• Assessed compound efficacy in C26 tumor-conditioned cell models and C26 tumor-bearing mouse models.
• Performed pharmacokinetic studies to determine compound stability and bioavailability.

Main Results:

• Compound 10 was identified as the lead derivative.
• In vitro, compound 10 reversed myotube atrophy by 67.08% and reduced adipocyte lipolysis.
• In vivo, compound 10 alleviated cachexia-related weight loss in tumor-bearing mice without affecting tumor growth.
• Pharmacokinetic analysis showed compound 10 possesses enhanced stability with a half-life of 11.1 hours and an AUC0-t of 8369 ng/mL.

Conclusions:

• Compound 10 is a promising therapeutic candidate for managing cancer cachexia.
• The rational design strategy provides a framework for optimizing other natural products.
• The enhanced metabolic stability and efficacy of compound 10 warrant further clinical investigation.